Arcturus Therapeutics Holdings Inc News - ARCT | ADVFN

Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc (ARCT) News

Arcturus Therapeutics Holdings Inc (ARCT)

14.82

-0.91

(-5.79%)

At close: December 18 4:00PM

Delayed by 15 minutes

14.82

0.00

( 0.00% )

After Hours: 4:30PM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Form 4 - Statement of changes in beneficial ownership of securities

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the...

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the...

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the...

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as...

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the...

Form 8-K - Current report

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Cystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with...

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused...

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12...

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying...

Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Approval underscores CSL and Arcturus Therapeutics’ commitment to delivering disruptive technologies to combat COVID-19 and other respiratory...

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the...

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the...

1
Next

Monksdream

Monksdream 3 months ago

ARCT a buy again

Monksdream

Monksdream 4 months ago

That awful Cathie Wood has been a recent buyer

Monksdream

Monksdream 4 months ago

ARCT 10Q due AUGUST5

Monksdream

Monksdream 9 months ago

ARCT 10Q due March 7

Monksdream

Monksdream 10 months ago

ARCT new 52 week high

Monksdream

Monksdream 1 year ago

Arcturus Therapeutics (ARCT)
icon-fall
19%
Shares of Arcturus Therapeutics traded down ~19% on Tuesday after the company announced4 lower-than-expected revenue and earnings for the second quarter. According to management, revenue declined in response to the termination of two agreements, one with Vinbiocare and another with the Israeli Ministry of Health. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.

Monksdream

Monksdream 1 year ago

Arcturus Therapeutics Holdings Inc NASDAQ: ARCT

GoSymbol lookup
Health Care : Biotechnology | Small Cap GrowthCompany profile
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform

and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.

Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.

IOUBLOKE1

IOUBLOKE1 3 years ago

Silence is golden ARC

IOUBLOKE1

IOUBLOKE1 3 years ago

Wow big after hours green buy

IOUBLOKE1

IOUBLOKE1 3 years ago

Spike delivers in Canada 400 million does

make it happen

make it happen 3 years ago

http://archive.fast-edgar.com/20210812/A2Z2M22C3Z2232K222JN2CZ272FUV22SE232/ another company that directs them selling out potentially seems like a big negative along with many downgrades over $20.00 less than current PPS

Smknf250

Smknf250 3 years ago

I don’t see any filing that reflects that. Where do you see it?

make it happen

make it happen 3 years ago

Director sold 725,000 shares @ $55.44 and 25,000 @ $45.83 total of 800,000 shares

Capitalization at it's finest, run for the hills. imho

bounce off 30's then into 20's

make it happen

make it happen 3 years ago

B. Wriley Price target $27.00. Price Per Share PPS is $47.00. Only $20.00 to drop to hit raised price target.

make it happen

make it happen 3 years ago

$1.40* opps

1-7 R/S

Sold drug in a few years will prob do another one sadly

make it happen

make it happen 3 years ago

Don't forget was like $1.10 at one point. Only 2 mil Revenue VS 2.7 expected.. while losing 56.4 mil in the second quarter or over 225,000,000 million loss for the year.

-$225,000,000 vs maybe 4 mil on a good year

Downgraded to under preform

Sold the drug now have nada

Also had nice size R/S in the past

make it happen

make it happen 3 years ago

Posted Revenue of $2 million vs estimated 2.7 mil.

Loss of $56.4 million second quarter only.

Huge differences

Sold the drug... No mo

Down graded to underperform

make it happen

make it happen 3 years ago

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Oh no...

dinogreeves

dinogreeves 3 years ago

ARCT the next NVAX.

Cosa

Cosa 3 years ago

might be getting squeezed, the float is so low.

Cosa

Cosa 3 years ago

wow this is pumping

Atown62

Atown62 4 years ago

Clemdane

Clemdane 4 years ago

Still long here. This is a looong term buy. Disappointing that we got that massive haircut, but we've had them before and recovered. It's the nature of this volatile sector.

Atown62

Atown62 4 years ago

lecorb

lecorb 4 years ago

In TDAmeritrade. TIPRANKS 7 SCROE PT: $88.25
Analyst Ratings, Moderate Buy! Last actualitation!
Based on the 10 sell-sidetooltipClick this button to read the definition of sell-side analysts who offered a 12-month price target in the last three months. Analysts predict a(n) 122.80% increase from today.
Kumaraguru Raja
Brookline Capital Markets
5Stars target $102.00rankingBuyanalystAction
Maintained date 2 days ago
analyst
Steven Seedhouse
Raymond James
5 Stars target ranking Hold analystAction Downgraded date 2 days ago
analyst
Yasmeen Rahimi
Piper Sandler
5Star target $140.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Seamus Fernandez
Guggenheim
5 Stars target -- ranking Buy analystAction Maintained date
2 days ago
Madhu Kumar
Robert W. Baird
5 Stars target $69.00 ranking Hold analystAction Downgraded
date
2 days ago
analyst
Elemer Piros
Roth Capital
5 Stars target $77.00 ranking Sell analystAction Maintained
date 2 days ago
Mayank Mamtani
B.Riley Financial
5 Stars target $138.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Yigal Nochomovitz
Citigroup
5Stars target $133.00 ranking Buy analystAction Maintained
date 17 days ago

sanderburwil

sanderburwil 4 years ago

Nope- was just a good “tax dump day” excuse today. Not holding- but really tempted- can only see upwards from here. Cathy woods didn’t sell a share today. Tells you something..

Willymon

Willymon 4 years ago

ARCT - Re-enter in the 30's. 34-37 seems to be my gate with this one.

The ol' "buy the rumor, sell the news" strikes again.

Or, today is last day to sell for 2020 taxes -- Dump day.

Take your pick.

It's a pandemic market and more crazy and unexpected things to come.

Remember, ARCT has a lot more to offer than just COVID solutions.

Their tech enables many other biotech companies delivery and replication methods.

ARCT has established a 52-wk high of $130.

Many think it will go past that.

ClayTrader

ClayTrader 4 years ago

* * $ARCT Video Chart 12-29-2020 * *

Link to Video - click here to watch the technical chart video

Clemdane

Clemdane 4 years ago

Wish I had flipped it. Hindsight is 20/20.

Willymon

Willymon 4 years ago

ARCT - Me as well. Been in-n-out four times with profits every time.

When I talk to others they never heard of ARCT.

Ready for the next leg.

Clemdane

Clemdane 4 years ago

I'm still in - going to see where the ride takes me

Willymon

Willymon 4 years ago

ARCT - Still going but nobody on iHub seems aware.

Some on Stocktwits saying this is going to $500-700.

I get 10x plays often, but this is a big 10x for sure.

whytestocks

whytestocks 4 years ago

JUST IN: $ARCT Why Arcturus Therapeutics Stock Soared Today

Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. The big jump came after the clinical-stage biotech provided its third-quarter update following the market close on Monday. Investors were less interested in Arcturus' fi...

In case you are interested ARCT - Why Arcturus Therapeutics Stock Soared Today

whytestocks

whytestocks 4 years ago

Breaking News: $ARCT Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 Arcturus ...

Find out more ARCT - Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Clemdane

Clemdane 4 years ago

I'm more amazed that anyone posted on this board. But I agree on the breakout!

Willymon

Willymon 4 years ago

ARCT - In it to win it.

Biggiee

Biggiee 4 years ago

Breakout! Blue skies.

Clemdane

Clemdane 4 years ago

Wow! Someone posted on the ARCT board. Thank you very much. I like your chart. I will put my faith in Fibonacci!

TFMG

TFMG 4 years ago

$ARCT | #ArcturusTherapeutics Breakout Alert

Potential long above $63.00
Upside Fibonacci target zone $76.00

Clemdane

Clemdane 4 years ago

Hello silent ARCT board. Just a message to say I am still here! Still long ARCT.

Clemdane

Clemdane 5 years ago

That's what I thought. Thank you.

Willymon

Willymon 5 years ago

$ARCT - Doesn't look like the two are comparable.

$ARCT's self replicating delivery method along with the protein they are developing to block the keyholes in the host (humans) the spikes on viruses need to infect the host is a unique approach. Can't spike into a receiving host keyhole, no infection or replication. Game over.

$ARCT would be one shot as a cure for nearly all viruses, including the common flu.

I'm also a little weary with all these biotechs promising cures so soon.

Rhinovirus(Flu/common cold) still has no vaccine which they have been working to cure since the 1950's.

$ARCT thinks they have the total solution.

Clemdane

Clemdane 5 years ago

Hey do you know anywhere with a good competitive analysis of ARCT vs. the Oxford University vaccine?

Clemdane

Clemdane 5 years ago

It's truly incredible. I'm thrilled to be here.

Willymon

Willymon 5 years ago

$ARCT - News out today. How you feeling about those 13's now?

pix

pix 5 years ago

Shortly they hopefully will give some details to preclinical studies...
If positive, watch out...

Willymon

Willymon 5 years ago

$ARCT - Singapore has set and is setting the example to follow in all this.

The fact that they selected $ARCT to develop a cure is very telling.

Arcturus announced that it is partnering with Duke-NUS, a partnership between the Duke University School of Medicine and the National University of Singapore, to develop a COVID-19 vaccine to prevent infection by the coronavirus. The government of Singapore will pay for the vaccine's development -- $10 million to be paid part up-front, part upon achievement of unspecified "development milestones." And Singapore will get first dibs on any vaccines produced (plus potential royalties on vaccine sales outside of Singapore).Link>

pix

pix 5 years ago

If approved in Singapore, they will get access to many Asian countries....

Clemdane

Clemdane 5 years ago

Incredible. I have it in an IRA. Going to try to get more.

Willymon

Willymon 5 years ago

$ARCT - $13.90 is sooner. Nobody here is even aware of them. And, with only 1100 on stocktwits, nobody there is aware.

If you buy at $50 and it goes to $110, you're still in profit. But, now we're into the "What IF" game. Have to be long on $ARCT.

If they come up with the Covid-19 vaccine, then that also means they also cured thousands of other viruses.

Their method is to provide humans with a way to clog the keyholes that the spikes on viruses need to plug into to infect and replicate.

They don't patent some of their methods on purpose because a patent must show exactly how something works. This is to their advantage so other biotech companies have to go figure it out on their own. Trade secret.

Arcturus Therapeutics

Delayed Upgrade Clock